Compare GFL & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GFL | VTRS |
|---|---|---|
| Founded | 2007 | 1961 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 14.2B |
| IPO Year | 2020 | N/A |
| Metric | GFL | VTRS |
|---|---|---|
| Price | $41.80 | $12.43 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 6 |
| Target Price | ★ $57.18 | $11.50 |
| AVG Volume (30 Days) | 1.7M | ★ 8.6M |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | 0.14% | ★ 3.85% |
| EPS Growth | N/A | N/A |
| EPS | ★ 6.65 | N/A |
| Revenue | $5,904,199,182.00 | ★ $14,124,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.24 | $1.18 |
| P/E Ratio | $5.87 | ★ N/A |
| Revenue Growth | ★ 27.49 | N/A |
| 52 Week Low | $41.29 | $6.85 |
| 52 Week High | $52.00 | $12.68 |
| Indicator | GFL | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 28.74 | 71.76 |
| Support Level | $42.71 | $12.19 |
| Resistance Level | $43.90 | $12.68 |
| Average True Range (ATR) | 0.70 | 0.27 |
| MACD | -0.12 | -0.00 |
| Stochastic Oscillator | 0.57 | 79.28 |
GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.